共 106 条
[1]
Armstrong AW(2021)Psoriasis prevalence in adults in the United States JAMA Dermatol 157 940-946
[2]
Mehta MD(2019)Psoriatic arthritis: what is happening at the joint? Rheumatol Ther 6 305-315
[3]
Schupp CW(2020)EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update Ann Rheum Dis 79 700-712
[4]
Gondo GC(2022)Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 Nat Rev Rheumatol 18 465-479
[5]
Bell SJ(2016)Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis Arthritis Rheumatol 68 1060-1071
[6]
Griffiths CEM(2020)Assessment of the many faces of PsA: single and composite measures in PsA clinical trials Rheumatology (Oxford) 59 i29-i36
[7]
Belasco J(2019)Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis Arthritis Rheumatol 71 5-32
[8]
Wei N(2021)Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults Expert Rev Clin Immunol 17 5-13
[9]
Gossec L(2020)Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial Lancet 395 1115-1125
[10]
Baraliakos X(2020)Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial Lancet 395 1126-1136